News and Events
Are you using the right reagents for Hemophilia testing?
Hemophilia testing is complicated – DiaPharma scientists can help you choose the right assays for your testing needs. We offer a variety of kits and reagents to measure FVIII and FIX. Contact us to learn more.
COAMATIC® FVIII (K822585)
COATEST® SP FVIII (K824086)
COATEST® SP4 FVIII (K824094)
● Contains bovine FIXa + FX reagents
● FDA-cleared
Technochrom FVIII 2G on Ceveron® s100*
● Automated sensitive FVIII assay
Technoclone Factor FVIII Inhibitor (Bethesda)* – fully automated coming soon!
Ceveron® TGA RB on Ceveron® s100*
● Automated, standardized thrombin generation assay
● Optimized for measurement of bleeding tendency, hemophilia research & development
● Explore thrombin generation assay options on the Ceveron s100
● Chromogenic FIX for Hemophilia B research
● Accurate and easy to use
*For research use only in US and Canada. Not for use in diagnostic procedures.
Solutions for Detection of Apoptosis in Oncology Xenograft Models
At DiaPharma, we specialize in biomarker assays designed to advance oncology research. One of the hallmarks of cancer is the evasion of apoptosis by tumor cells—making the detection of cellular death, especially apoptosis, a critical readout in the evaluation of anti-cancer therapies.
Xenograft models are widely used in oncology research to study cancer therapies in vivo. However, methods for evaluating the effect of potential drug candidates on tumor growth—such as volume measurements, imaging, or immunohistochemical staining—are often imprecise, expensive, technically demanding, or require sacrificing the xenograft host.
An alternative is the M30 Apoptosense® ELISA*.
What is the M30 Apoptosense® ELISA?
This blood-based biomarker assay utilizes the M30® antibody which specifically detects a caspase-cleaved fragment of cytokeratin 18 (CK18), a cytoskeletal protein expressed in epithelial cells and cleaved by caspases early during apoptosis. The cleaved CK18 fragment (ccK18) is released into the bloodstream, and its concentration in serum or plasma measured with the M30 Apoptosense® ELISA correlates with the extent of epithelial cell apoptosis.
Why choose the M30 Apoptosense® ELISA for use with your xenograft model?
● The M30® antibody is highly specific for human ccK18 and does not cross-react with murine proteins, enabling precise detection of apoptosis of human tumor cells with xenograft models.
● Minimally invasive blood sampling allows for longitudinal assessment of treatment response.
● The assay provides sensitive, quantitative measurements to evaluate dose- and time-dependent effects of potential drug candidates.
● Incorporating the M30® biomarker offers a robust, translational tool to strengthen efficacy assessments — particularly valuable for bridging preclinical findings to clinical applications.
We would be happy to provide more detailed information tailored to your research. Please don’t hesitate to reach out to our Scientists or your local DiaPharma Territory Manager.
*For research use only in US and Canada. Not for use in diagnostic procedures.
-
ISTH 2025 Was Hot—in More Ways Than One!
Posted: July 23, 2025
ISTH 2025 brought the heat this year—both in scientific content and in temperature! While Washington, D.C. was under a heat advisory during the 33rd Congress of the International Society on Thrombosis and Haemostasis, that didn’t stop thousands of dedicated clinicians, researchers, and industry professionals, including a large team from DiaPharma, from coming together for an…
-
DiaPharma at ISTH 2025
Posted: June 27, 2025
See what we unveiled at ISTH 2025! VIEW VIDEO We are grateful for the opportunity to connect and discuss the latest advancements for the hemostasis laboratory at ISTH 2025. The science and collaboration were outstanding. Many thanks to all who worked so hard to make it a success! DiaPharma was proud to highlight: CLINICAL &…
-
Differential Discussions Guest Series: The Use of Chromogenic Factor X Assays for Monitoring Patients on Warfarin Therapy
Posted: April 11, 2025
David L. McGlasson, MS, MLS(ASCP) A recent episode of “Differential Discussions” digs into the utility of the chromogenic factor X (CFX) assay for monitoring patients on oral anticoagulant therapy (OAT). Data from previous studies and a case study were discussed. A study was presented that compared International Normalized Ratio (INR) values with CFX results, to…
-
The (im)Balance of NETosis, Platelets, VWF, and ADAMTS13 During Immunothrombosis
Posted: December 10, 2024
-Contributed by Abi Kasberg, PhD Immunothrombosis defines the delicate intersection of innate immunity and coagulation. This complex bidirectional interaction between the immune system and clotting components activate each other, leading to abnormal clotting events when unbalanced. A central component to immunothrombosis is the NETosis response of activated neutrophils that result in the expulsion of neutrophil…
-
Extended half-life (EHL) testing for FVIII and FIX therapies
Posted: November 13, 2024
David McGlasson The complexities of testing for hemophilia A and B are vast. This Clot Club post serves as an overview of what the laboratory must consider when testing for new EHL products. When comparing different methods used to determine FVIII and FIX activity, the testing laboratory should evaluate the calibrators used, individual kit…
-
One Week in Bangkok – Thoughts on ISTH 2024
Posted: July 10, 2024
Jennifer J. Kiblinger Scientific Director First, I need to comment how amazing the people of Thailand were. This introvert was a bit worried about going to such a crowded city, but everyone was so hospitable. At the hotel, at the convention center, on the public transit. Those of you who stayed to the end perhaps…
-
CONTINUING CONTROVERSY ON USING A NORMALIZATION CALCULATION ON DILUTE RUSSELL VIPER TIME
Posted: May 9, 2024
David L. McGlasson, MS, MLS(ASCP) Several years ago, I was the lead author of a manuscript titled: Comparison of six dilute Russell Viper Venom Time (DRVVT) lupus anticoagulant (LA) screen/confirm assay kits.1 The purpose of the protocol was to see if using normalized ratio gave our laboratory any better inter-method consistency when performing the DRVVT…
-
Do We Need To Standardize Coagulation Nomenclature In Today’s Laboratory Environment?
Posted: December 21, 2023
David L. McGlasson, MS, MLS(ASCP) A few months ago, I posted on LinkedIn that I noticed at recent conferences and journal articles that blood coagulation factors were sometimes referred to in Euro-Arabic numbers (E-A), 0 through 9, instead of Roman numerals.For example, “F8” was written instead of “FVIII”.And sometimes they are used interchangeably. I received…
-
The standardization of NET measurements, a work in progress.
Posted: October 5, 2023
-Contributed by Abi Kasberg, PhD and Olivia Stricker, PhD Neutrophil extracellular traps (NETs) are an amazing participant of the innate immune system. In a first line of defense, neutrophils expel decondensated chromatin into the extracellular matrix to trap invading pathogens in a mechanism called NETosis. NETs are made up of DNA, histones, and granule…
-
A Review of the XXXVth International Symposium on Technical Innovations in Laboratory Hematology 2023 (ISLH 2023)
Posted: September 8, 2023
David L. McGlasson, MS, MLS(ASCP) The most recent ISLH meeting was held in New Orleans, LA May 11-13, 2023. The conference had many State-of-the-Art sessions and I concentrated on the hemostasis/thrombosis presentations. On the first day, Katrien Devreese MD, PhD, Ghent University Hospital, Belgium gave an excellent presentation on the current Diagnosis of Acquired Thrombotic…
-
Should Direct Oral Anticoagulants (DOAC) be Used in Individuals with Antiphospholipid Syndrome (aPS) vs Long Term Warfarin Treatment?
Posted: April 14, 2023
David L. McGlasson, MS, MLS(ASCP) At the recent HTRS 2023 Scientific Symposium, a lively discussion in a Plenary Session was presented titled, “Do We Dare to DOAC?” The HTRS session was moderated by Ayesha N. Zia MD, MSCS and Bethany T. Samuelson, MD, and included three presenters: Introduction to Science: Stephan Moll, MD, University of…
-
Grant Opportunity from DiaPharma
Posted: April 13, 2023
Why isn’t this being funded?! Thoughts from HTRS 2023, and a grant opportunity from DiaPharma Jennifer J. Kiblinger Scientific Director The HTRS 2023 Scientific Symposium gave new insights in hemostasis and thrombosis, from health justice initiatives to the latest in antiphospholipid antibody testing. There were lively and insightful debates, even one on how many steel…
-
CHOOSING WISELY – Coagulation Testing Recommendations
Posted: January 25, 2023
David L. McGlasson, MS, MLS(ASCP) Choosing Wisely is a United States-based health educational campaign led by the American Board of Internal Medicine Foundation (ABIMF) and the Consumers’ Union to reduce the prevalence of unnecessary diagnostic tests and treatments.1 The Choosing Wisely campaign goal is to disseminate information for clinicians and patients that provides diagnostic care…
-
THSNA 2022 Recap
Posted: October 7, 2022
Chicago, IL, August 15-18, 2022 David L. McGlasson, MS, MLS(ASCP) The recent THSNA 2022 meeting that was held in Chicago, IL from August 15-18, 2022, was a welcome event, as attendees for the first time in a couple of years could attend the conference in person or virtually. Finally, attendees had the ability to…
-
VACCINE-INDUCED THROMBOTIC THROMBOCYTOPENIA (VITT): INSIGHTS FROM ISTH 2022
Posted: September 26, 2022
– Contributed by Abi Kasberg, PhD Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare and severe complication of adenoviral-based COVID-19 vaccinations. VITT occurs at a rate of 1:100,000 to 1:1,000,000 and is associated with high morbidity and mortality. Long term complications of VITT and VITT antibodies can persist for more than 9 months and has…
-
Emerging Therapeutic Targets for Hereditary Angioedema
Posted: August 31, 2022
-Contributed by Abi Kasberg, PhD Hereditary Angioedema (HAE) is a rare, inherited, autosomal dominant disorder that is characterized by fluid accumulation and tissue swelling that can be painful and potentially life-threatening. This form of angioedema is driven by vasculature leakage into surrounding tissues including in the hands, feet, lips, genitals, gastrointestinal tract, or airway. Normal…
-
CHROMOGENIC FACTOR X ASSAYS vs the PT/INR TO MONITOR SUBJECTS ON COUMADIN THERAPY WHEN AN INDIVIDUAL APPROACH IS NECESSARY
Posted: June 28, 2022
INTRODUCTION In a previous CLOT CLUB blog post I discussed how chromogenic factor X assays (CFX) were more accurate and less likely to be influenced in certain instances than using the prothrombin time/international ratio assay (PT/INR)1. The PT/INR may be falsely elevated in the presence of lupus anticoagulants (LA), direct thrombin inhibitors (DTI), and dysfibrinogenemia. …
-
COMPREHENSIVE PRIMARY HEMOSTASIS ASSESSMENTS TO DIAGNOSE AND MONITOR VWD
Posted: April 11, 2022
-Contributed by Abi Kasberg, PhD Von Willebrand disease (VWD) is an inherited bleeding disease that clinically presents with extended bleeding times following wounds, surgeries, nosebleeds, or during menstruation. VWD affects approximately 0.1% of people and is considered to be the most common bleeding disorder (Keesler and Flood 2017). Von Willebrand factor (vWF) is a multimer…
-
POTENTIAL FUTURE USES FOR RECOMBINANT ADAMTS13
Posted: March 25, 2022
David L. McGlasson, MS, MLS(ASCP) Before reading this blog post, I invite the viewer to read the article by Abi Kasberg, PhD posted August 21, 2021 titled Thrombotic Thrombocytopenic Purpura (TTP) Clinical Trials: Targeting the needs left by current treatment options. It’s a great review of current methods to address ADAMTS13 deficiency and discusses the…
-
THE NEW NOVEL ANTICOAGULANTS XI(a) and XII(a). THE CONTACT FACTOR INHIBITORS: Battling thromboembolism.
Posted: December 17, 2021
THE NEW NOVEL ANTICOAGULANTS XI(a) and XII(a). THE CONTACT FACTOR INHIBITORS: Battling thromboembolism. David L. McGlasson, MS, MLS(ASCP) INTRODUCTION Thromboembolism is a leading cause of mortality and morbidity. Treatment with anticoagulants is prescribed, but balancing bleeding and clotting has been a challenge. In the 1940s, unfractionated heparin (UFH) became available for use by intravenous or…